Document is current
Any future updates will be listed below
-
Authors
Doward, Lynda C.
Breckons, Matthew
Balp, Maria-Magdalena
Twiss, James
Vale, Luke
McSweeney, Lorraine
Brass, Clifford A.
Anstee, Quentin M.
Sanyal, Arun J.
-
Funding
Funding for this research was provided by:
Novartis Pharma AG (Not applicable)
- License Information
-
More Information
Article History
Received: 1 September 2024
Accepted: 15 April 2025
First Online: 1 July 2025
Declarations
:
: The Western Institutional Review Board approved the research conducted with patients in the US. The London-Stanmore Research Ethics Committee provided National Health Service (NHS) ethics approval for the research conducted with UK participants, and the Health Research Authority granted permission to conduct the study (Reference: 18/LO/1594). The study was conducted in accordance with the Declaration of Helsinki, and all participants provided informed consent before taking part in the study.
: Not applicable.
: This study was completed under a research contract between RTI Health Solutions and Novartis Pharma AG and was funded by Novartis Pharma AG. LD and JT are salaried employees of RTI Health Solutions. MMB is a salaried employee of Novartis Pharma AG. CAB was a salaried employee of Novartis Pharmaceuticals Inc. at the time the study was conducted. QMA is coordinator of the EU Innovative Medicines Initiative (IMI-2) LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. This multistakeholder consortium includes industry partners. QMA has received research grant funding from AstraZeneca, Boehringer Ingelheim, and Intercept Pharmaceuticals, Inc.; has served as a consultant on behalf of Newcastle University for Alimentiv, Akero, AstraZeneca, Axcella, 89bio, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genfit, Genentech, Gilead, GSK, Hanmi, HistoIndex, Intercept Pharmaceuticals, Inc., Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGM Bio, Novartis, Novo Nordisk, PathAI, Pfizer, Poxel, Resolution Therapeutics, Roche, Ridgeline Therapeutics, RTI, Shionogi, and Terns; has served as a speaker for Fishawack, Integritas Communications, Kenes, Madrigal, Medscape, Novo Nordisk, and Springer Healthcare; and receives royalties from Elsevier Ltd. MB, LMc, and LV are or were employees of Newcastle University at the time this work was conducted.
